

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥(煙台)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

POLL RESULTS OF THE 2023 ANNUAL GENERAL MEETING

Reference is made to the circular (the “Circular”) of RemeGen Co., Ltd.* 榮昌生物製藥(煙台)股份有限公司 (the “Company”) incorporating, amongst others, the notice (the “Notice”) of 2023 annual general meeting (the “AGM”) dated May 29, 2024. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

ATTENDANCE AT THE AGM

The Board is pleased to announce that the AGM was held at Room 6134, Phase III Building of the Company at 58 Middle Beijing Road, Yantai Development Zone, Yantai Area of Shandong Pilot Free Trade Zone, PRC on Friday, June 28, 2024 at 2:00 p.m.

The attendance of the AGM was as follows:

Class of Shares	Number of Shares in issue (and entitling holders to attend and vote for or against resolutions)	Number of Shares present (in person or by proxy)	Approximate % of Shares present (in person or by proxy)
A Shares	354,750,844	204,949,359	37.6515%
H Shares	189,581,239	32,260,712	5.9267%
Total	544,332,083	237,210,071	43.5782%

As stated in the Circular, Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Lin Jian and Dr. Wang Liqiang, the Controlling Shareholders, and their associates, holding an aggregate of 218,032,173 Shares, were required to, and did, abstain from voting on the resolutions numbered 12 and 13 in relation to the adjustment to the amounts of the expected day-to-day related (connected) transactions for the years 2024 and 2025.

Saved as disclose above, to the best knowledge, information and belief of the Company: (1) there were no Shares entitling the holder to attend and abstain from voting in favour of the resolutions proposed at the AGM as set out in Rule 13.40 of the Listing Rules; (2) no Shareholder was required under the Listing Rules to abstain from voting on the resolutions proposed at the AGM; and (3) no party has stated any intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the AGM.

The AGM was convened by the Board. All Directors attended the AGM.

POLL RESULTS OF THE AGM

The poll results of the AGM were as follows:

Ordinary Resolutions		Number of votes and percentage of the total voting shares at the AGM			Passed by Shareholders
		For	Against	Abstain	
1.	To consider and approve the report on the work of the Board of Directors of the Company for the year 2023.	237,197,682 99.9948%	6,389 0.0027%	6,000 0.0025%	Yes
2.	To consider and approve the report on the work of the Supervisory Committee of the Company for the year 2023.	237,197,682 99.9948%	6,389 0.0027%	6,000 0.0025%	Yes
3.	To consider and approve the financial accounts report of the Company for the year 2023.	237,197,682 99.9948%	6,389 0.0027%	6,000 0.0025%	Yes
4.	To consider and approve the full text of annual report of the Company for the year 2023 and its summary.	237,197,682 99.9948%	6,389 0.0027%	6,000 0.0025%	Yes
5.	To consider and approve the annual profit distribution plan of the Company for the year 2023.	237,197,682 99.9948%	6,389 0.0027%	6,000 0.0025%	Yes
6.	To consider and approve the re-appointment of 2024 domestic and foreign accounting firms.	237,197,682 99.9948%	6,389 0.0027%	6,000 0.0025%	Yes

Ordinary Resolutions		Number of votes and percentage of the total voting shares at the AGM			Passed by Shareholders
		For	Against	Abstain	
7.	To consider and confirm the remuneration of Directors of the Company.	237,197,682 99.9948%	6,389 0.0027%	6,000 0.0025%	Yes
8.	To consider and confirm the remuneration of Supervisors of the Company.	237,197,682 99.9948%	6,389 0.0027%	6,000 0.0025%	Yes
Special Resolutions		Number of votes and percentage of the total voting shares at the AGM			Passed by Shareholders
		For	Against	Abstain	
9.	To consider and approve the general mandate to issue additional shares of the Company.	231,261,042 97.4921%	5,943,029 2.5054%	6,000 0.0025%	Yes
10.	To consider and approve the change of registered capital and the amendments to the Articles of Association of the Company.	237,197,682 99.9948%	6,389 0.0027%	6,000 0.0025%	Yes
Ordinary Resolutions		Number of votes and percentage of the total voting shares at the AGM			Passed by Shareholders
		For	Against	Abstain	
11.	To consider and approve the amendments to certain internal management policies of the Company:				
	11.1 the amendments to the Management Policy for Related (Connected) Transactions.	237,197,682 99.9948%	6,389 0.0027%	6,000 0.0025%	Yes
	11.2 the amendments to the Management Policy for Raised Proceeds.	237,197,682 99.9948%	6,389 0.0027%	6,000 0.0025%	Yes
12.	To consider and approve the adjustment of the cap of related (connected) transactions for 2024 between RemeGen and MabPlex in respect of the master service.	44,394,550 99.9721%	6,389 0.0144%	6,000 0.0135%	Yes
13.	To consider and approve the adjustment of the caps of related (connected) transactions for 2024-2025 between RemeGen and CelluPro Biotechnology in respect of materials purchase.	44,394,550 99.9721%	6,389 0.0144%	6,000 0.0135%	Yes

As more than half of the votes casted in favour of the above ordinary resolutions numbered 1 to 8 and 11 to 13, these resolutions were duly passed.

As not less than two-thirds of the votes casted in favour of the above special resolutions numbered 9 to 10, these resolutions were duly passed.

The H share registrar of the Company, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM. One representative of the Shareholders, two lawyers of King & Wood Mallesons and one supervisor of the Company participated in the scrutiny of the poll results.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive director

Yantai, The People's Republic of China
June 28, 2024

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive Directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive Directors, and Mr. Hao Xianjing, Dr. Ma Lan and Mr. Chen Yunjin as the independent non-executive Directors.

* *For identification purposes only*